HomeCompareNVIV vs QYLD

NVIV vs QYLD: Dividend Comparison 2026

NVIV yields 623.64% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVIV wins by $353147.43M in total portfolio value
10 years
NVIV
NVIV
● Live price
623.64%
Share price
$0.32
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$353147.46M
Annual income
$268,464,858,212.91
Full NVIV calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — NVIV vs QYLD

📍 NVIV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVIVQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVIV + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVIV pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVIV
Annual income on $10K today (after 15% tax)
$53,009.04/yr
After 10yr DRIP, annual income (after tax)
$228,195,129,480.97/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, NVIV beats the other by $228,195,124,670.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVIV + QYLD for your $10,000?

NVIV: 50%QYLD: 50%
100% QYLD50/50100% NVIV
Portfolio after 10yr
$176573.74M
Annual income
$134,232,431,936.12/yr
Blended yield
76.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NVIV right now

NVIV
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-38.6
Piotroski
2/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVIV buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVIVQYLD
Forward yield623.64%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$353147.46M$25.4K
Annual income after 10y$268,464,858,212.91$5,659.31
Total dividends collected$346135.20M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: NVIV vs QYLD ($10,000, DRIP)

YearNVIV PortfolioNVIV Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$73,064$62,363.58$10,352$1,192.36+$62.7KNVIV
2$504,020$425,841.72$10,830$1,347.57+$493.2KNVIV
3$3,284,735$2,745,434.16$11,460$1,539.07+$3.27MNVIV
4$20,236,353$16,721,686.56$12,275$1,777.84+$20.22MNVIV
5$117,931,146$96,278,247.94$13,323$2,078.95+$117.92MNVIV
6$650,559,742$524,373,415.78$14,667$2,463.34+$650.55MNVIV
7$3,399,531,572$2,703,432,648.58$16,396$2,960.57+$3399.52MNVIV
8$16,840,226,624$13,202,727,840.99$18,631$3,612.97+$16840.21MNVIV
9$79,142,617,279$61,123,574,791.73$21,548$4,482.15+$79142.60MNVIV
10$353,147,458,701$268,464,858,212.91$25,398$5,659.31+$353147.43MNVIV

NVIV vs QYLD: Complete Analysis 2026

NVIVStock

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Full NVIV Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this NVIV vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVIV vs SCHDNVIV vs JEPINVIV vs ONVIV vs KONVIV vs MAINNVIV vs XYLDNVIV vs JEPQNVIV vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.